EP 3843745 A1 20210707 - METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
Title (en)
METHODS AND COMPOSITIONS FOR TREATING NEUROBLASTOMA IN A JUVENILE MAMMALIAN BODY
Title (de)
VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEUROBLASTOM BEI EINEM JUVENILEN SÄUGETIERKÖRPER
Title (fr)
PROCÉDÉS ET COMPOSITIONS POUR LE TRAITEMENT DE NEUROBLASTOME DANS UN CORPS DE MAMMIFÈRE JUVÉNILE
Publication
Application
Priority
- US 201862723592 P 20180828
- US 2019048579 W 20190828
Abstract (en)
[origin: WO2020047103A1] Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.
IPC 8 full level
A61K 31/54 (2006.01); A61K 31/541 (2006.01); A61K 31/549 (2006.01)
CPC (source: EP KR)
A61K 9/0019 (2013.01 - EP KR); A61K 9/14 (2013.01 - EP); A61K 9/5146 (2013.01 - KR); A61K 9/5153 (2013.01 - KR); A61K 31/198 (2013.01 - EP); A61K 31/4745 (2013.01 - EP); A61K 31/475 (2013.01 - EP); A61K 31/549 (2013.01 - EP KR); A61K 31/555 (2013.01 - EP); A61K 31/675 (2013.01 - EP); A61K 33/243 (2019.01 - EP); A61K 35/00 (2013.01 - EP); A61K 45/06 (2013.01 - EP KR); A61K 47/10 (2013.01 - EP); A61K 47/60 (2017.08 - EP KR); A61P 35/00 (2018.01 - EP KR); A61K 9/5146 (2013.01 - EP); A61K 9/5153 (2013.01 - EP)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2020047103 A1 20200305; AU 2019330831 A1 20210429; CA 3111015 A1 20200305; CN 113164491 A 20210723; EP 3843745 A1 20210707; EP 3843745 A4 20220615; JP 2021535173 A 20211216; JP 7530351 B2 20240807; KR 20210050543 A 20210507
DOCDB simple family (application)
US 2019048579 W 20190828; AU 2019330831 A 20190828; CA 3111015 A 20190828; CN 201980071376 A 20190828; EP 19855576 A 20190828; JP 2021511655 A 20190828; KR 20217008970 A 20190828